Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cytisinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 12/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 12/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 9/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 9/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 4/20 | 1.00 |
| ▸ | CHRNG | P07510 | 4/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 4/20 | 1.00 |
| ▸ | CHRND | Q07001 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytisinicline SCHEMBL13595657 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL8309064 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL1500421 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL14870500 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL472026 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL19877933 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL29903945 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL1500403 | 0.93 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL20680760 | 0.91 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL20680750 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3480 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748444-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-12612406-B2 | Cytisine salts | ACHIEVE LIFE SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4027815-B1 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | ACHIEVE LIFE SCIENCES INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4072517-B1 | LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CYTISINE | ADAMED PHARMA S A (PL) | 2026-04-01 | — | — | EP | claimed |
| EP-4704838-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4529924-B1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING CYTISINE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2026-02-18 | — | — | EP | claimed |
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | UNIV INDIANA RES & TECH CORP (US) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4673145-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CYTISINE | Adamed Pharma S.A. (PL) | 2026-01-07 | — | — | EP | claimed |
| EP-3746102-B1 | METHOD FOR ISOLATION OF CYTISINE | SOPHARMA AD (BG) | 2025-11-05 | — | — | EP | claimed |
| CN-1295076-A | Sophorine extracting process | JIANGXI TRADITIONAL CHIENSE ME (CN) | 2001-05-16 | — | — | CN | claimed |
| US-6194397-B1 | ENZYME INHIBITORS OF ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE; INCREASED HEPATOPROTECTIVE AND ANTIENZYME ACTIVITIES; N'-SUBSTITUTED PHOSPHONOALKYL-, PHOSPHONO- OR THIOPHOSPHONOCYTISINES | VITIK ANDREJ ZINOVYEVICH (KR) | 2001-02-27 | — | — | US | claimed |
| US-6126924-A | Light responsive self-tanning products and methods for use | SCALES-MEDEIROS VIRGINIA A (US) | 2000-10-03 | — | — | US | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
| WO-2000026392-A2 | MUTANT MOUSE CONTAINING A KNOCKOUT MUTATION IN DNA ENCODING AN ENDOGENOUS α4 SUBUNIT OF NICOTINIC ACETYLCHOLINE RECEPTOR | INSTITUT PASTEUR (FR) | 2000-05-11 | — | — | WO | claimed |
| US-6036973-A | Therapy for neurological diseases | ALZA CORPORATION (US) | 2000-03-14 | — | — | US | claimed |
| EP-0857172-B1 | PHOSPHORUS CONTAINING CYTHESINE DERIVATIVES | VITIK ANDREJ ZINOVYEVICH (KZ) | 1999-08-04 | — | — | EP | claimed |
| CN-1180074-A | Extraction of sophora alopecuroides extract and its composition | UNIV SHANDONG AGRICULTURAL (CN) | 1998-04-29 | — | — | CN | claimed |
| EP-0581457-A1 | Use of cytisine compounds for the manufacture of a medicament for the treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| US-5242916-A | Administering cystisine or its derivative for treatment of alzheimer*s or parkinson*s disease | R. J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-07 | — | — | US | claimed |